Showing posts with label Breast Cancer. Show all posts
Showing posts with label Breast Cancer. Show all posts

Wednesday, March 3, 2010

Researchers: Gene Test Could Help Breast Cancer Treatment


A new technique that links genes to a patient's response to chemotherapy for breast cancer could help doctors find more effective cancer treatments in the future. Our correspondent spoke to the British doctor who is leading the research.

The research is collaboration between scientists in Belgium, Denmark, the United States and Great Britain. They have identified six genes that impact whether a common form of chemotherapy, called paclitaxel is effective against breast cancer. Doctor Charles Swanton of the London Research Institute led the study.

"Potentially we have the opportunity now to I hope in the future to develop new ways of predicting which patients will specifically benefit from defined drugs, to better target the right drugs to the patients most likely to benefit," said Dr. Swanton. "But also, in the future we hope to identify new drugs that patients who have cancers that are resistant to conventional therapy, to try to identify new drugs that these specific patients may benefit from using tool like this."

Dr. Swanton says the research is in its early stages and that it will be years before it could be used in a normal medical setting. Still, he says, it has a lot of potential.

"It's a first small step in a much bigger scientific endeavor," he said.

By eliminating treatments that won't work for a patient, it could make it easier to determine which medicines will work. Swanton says this technique may also be effective or other types of cancers where the same genes have been spotted.

"That's the way we hope medicine is heading where each patient is treated differently, based on the expression of genes within the tumor or indeed the expression or sequence of specific genes within the patient," said Charles Swanton.

He says while this is a breakthrough, there is no guarantee of success. Years of research and clinical trials are needed.

Thursday, December 10, 2009

Dietary Soy linked to Lower Risk for Breast Cancer Death, Recurrence


December 8, 2009 — Dietary soy intake among Chinese women with breast cancer is significantly associated with lower risk for death and recurrence, according to the results of a large, population-based cohort study reported in the December 9 issue of the Journal of the American Medical Association.


"Soy foods are rich in isoflavones, a major group of phytoestrogens that have been hypothesized to reduce the risk of breast cancer," write Xiao Ou Shu, MD, PhD, from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues. "However, the estrogen-like effect of isoflavones and the potential interaction between isoflavones and tamoxifen have led to concern about soy food consumption among breast cancer patients."

The study goal was to determine the association of dietary soy intake after diagnosis of breast cancer with total mortality and cancer recurrence. In the Shanghai Breast Cancer Survival Study of 5042 female breast cancer survivors in China, women 20 to 75 years of age who were diagnosed between March 2002 and April 2006 were recruited and followed-up through June 2009.

At about 6 months after cancer diagnosis, participants provided information on cancer diagnosis and treatment, lifestyle exposures after cancer diagnosis, and disease progression. Three follow-up interviews at 18, 36, and 60 months after diagnosis allowed updating of this information. To obtain survival information for participants who were lost to follow-up, the investigators used annual record linkage with the Shanghai Vital Statistics Registry database. Disease and treatment information were verified from medical record review.

Primary study endpoints were total mortality and breast cancer recurrence or breast cancer–related deaths. Adjustment for known clinical predictors and other lifestyle factors was performed using Cox regression analysis, with dietary soy intake treated as a time-dependent variable. Median follow-up was 3.9 years (range, 0.5 - 6.2 years).